(Q53224717)

12 May 2018

title

Recombinant Shiga toxin B subunit elicits protection against Shiga toxin via mixed Th type immune response in mice. (English)

1 reference

12 May 2018

author name string

Pallavi Gupta

1

1 reference

12 May 2018

Manglesh Kumar Singh

2

1 reference

12 May 2018

Yamini Singh

3

1 reference

12 May 2018

Vandana Gautam

4

1 reference

12 May 2018

Subodh Kumar

5

1 reference

12 May 2018

Om Kumar

6

1 reference

12 May 2018

Ram Kumar Dhaked

7

1 reference

12 May 2018

language of work or name

English

0 references

publication date

19 August 2011

1 reference

12 May 2018

published in

Vaccine

1 reference

12 May 2018

volume

29

1 reference

12 May 2018

issue

45

1 reference

12 May 2018

page(s)

8094-8100

1 reference

12 May 2018

Enterohemorrhagic Escherichia coli: a family of emerging pathogens

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.040

The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.040

Pathogenesis of Shigella diarrhea. IX. Simplified high yield purification of Shigella toxin and characterization of subunit composition and function by the use of subunit-specific monoclonal and polyclonal antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.040

Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.040

Shiga toxin attacks bacterial ribosomes as effectively as eucaryotic ribosomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.040

Verotoxin receptor glycolipid in human renal tissue.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.040

Nontoxic Shiga toxin derivatives from Escherichia coli possess adjuvant activity for the augmentation of antigen-specific immune responses via dendritic cell activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.040

The 13C4 monoclonal antibody that neutralizes Shiga toxin Type 1 (Stx1) recognizes three regions on the Stx1 B subunit and prevents Stx1 from binding to its eukaryotic receptor globotriaosylceramide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.040

The B subunit of Shiga toxin coupled to full-size antigenic protein elicits humoral and cell-mediated immune responses associated with a Th1-dominant polarization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.040

Development of a hybrid Shiga holotoxoid vaccine to elicit heterologous protection against Shiga toxins types 1 and 2☆

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.040

Antibodies against recombinant shiga toxin subunit B neutralize shiga toxin toxicity in HeLa cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.040

Protection against Shiga toxin-producing Escherichia coli infection by transcutaneous immunization with Shiga toxin subunit B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.040

Antibody response to Shiga toxins Stx2 and Stx1 in children with enteropathic hemolytic-uremic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.040

Production of secretory immunoglobulin A against Shiga toxin-binding subunits in mice by mucosal immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.040

Sulfhydryl-based tumor antigen-carrier protein conjugates stimulate superior antitumor immunity against B cell lymphomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.040

A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.040

Induction of MHC class I presentation of exogenous antigen by dendritic cells is controlled by CD4+ T cells engaging class II molecules in cholesterol-rich domains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.040

Mouse toxicity and cytokine release by verotoxin 1 B subunit mutants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.040

Cytokines in childhood hemolytic uremic syndrome and thrombotic thrombocytopenic purpura

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.040

Escherichia coli Shiga toxin 1 and TNF-alpha induce cytokine release by human cerebral microvascular endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.040

Purification and characterization of human fibroblast-derived hybridoma growth factor identical to T-cell-derived B-cell stimulatory factor-2 (interleukin-6).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.040

The role of human interleukin-6 in B-cell isotype regulation and differentiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.040

Lymphokine control of in vivo immunoglobulin isotype selection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.040

Vaccines against intracellular infections requiring cellular immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.040

Towards the rational design of Th1 adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.040

Towards a comprehensive view of immunoglobulin class switching

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.040

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.040

Evidence that the A2 fragment of Shiga-like toxin type I is required for holotoxin integrity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.040

inferred from DOI database lookup

7 January 2021

based on heuristic

Purification of Shiga toxin and Shiga-like toxins I and II by receptor analog affinity chromatography with immobilized P1 glycoprotein and production of cross-reactive monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.040

inferred from DOI database lookup

7 January 2021

based on heuristic

Affinity purification and characterization of Shiga-like toxin II and production of toxin-specific monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.040

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2011.08.040

1 reference

12 May 2018

1 reference

12 May 2018